COCP Cocrystal Pharma, Inc.
Price Chart
Executive Summary
Cocrystal Pharma appointed James Sapirstein as CEO, replacing co-CEOs Sam Lee and James Martin, who remain as President/CSO and CFO respectively. The new CEO receives a $265,000 base salary, a 50% target bonus, and 235,000 stock options at $1.05 strike, with a second 235,000-option grant contingent on six-month performance. This is a routine executive succession with no material financial impact.
Actionable Insight
Monitor for any strategic shifts under new CEO, particularly pipeline prioritization or partnership activity, but this filing alone does not warrant a trading action. The next quarterly update (10-Q) will provide the first look at operational direction.
Key Facts
- James Sapirstein appointed CEO effective June 3, 2026, replacing co-CEOs Sam Lee and James Martin
- Sam Lee remains President and Chief Scientific Officer; James Martin remains CFO
- New CEO receives $265,000 annual base salary and 50% target performance bonus
- Initial inducement grant of 235,000 stock options at $1.05 strike, vesting over 4 years
- Contingent grant of additional 235,000 options at six-month anniversary, subject to performance targets
- Sapirstein previously served as CEO of Entero Therapeutics (ENTO) from Oct 2019 to Feb 2025
Financial Impact
CEO compensation package: $265,000 salary plus 235,000 options at $1.05 strike (approx. $247,000 intrinsic value at $1.05) with potential for another 235,000 options. Immaterial relative to company market cap of $14M.
Risk Factors
- New CEO lacks prior experience at Cocrystal Pharma and comes from a different therapeutic area (gastrointestinal vs antiviral)
- No change to the company's fundamental cash runway or development timeline
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027837 |
| Exhibit: ex10-1.htm | 0001493152-26-027837 |
| Document: 0001493152-26-027837-index-headers.html | 0001493152-26-027837 |
| Document: 0001493152-26-027837-index.html | 0001493152-26-027837 |
| Document: 0001493152-26-027837.txt | 0001493152-26-027837 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
4d ago
|
8-K
| $1.02 awaiting T+1 | awaiting T+1 | — | $0.9900 (−2.46%) |
|
Jun 3, 2026
10d ago
|
8-K
| $1.06 $1.05 | ▼ −0.94% | ▼ −1.34% | $0.9900 (−6.60%) |
|
May 27, 2026
16d ago
|
DEFA14A
| $1.13 $1.12 | ▼ −0.89% | ▼ −1.12% | $0.9900 (−12.39%) |
|
May 26, 2026
17d ago
|
8-K
| $1.13 $1.12 | ▼ −0.89% | ▼ −0.90% | $0.9900 (−12.39%) |
|
May 15, 2026
29d ago
|
Press Release
| $1.20 $1.18 | ▼ −1.67% | ▼ −1.60% | $0.9900 (−17.50%) |
|
May 4, 2026
5w ago
|
EFFECT
| $1.31 $1.38 | ▼ −5.34% | ▼ −4.55% | $0.9900 (+24.43%) |
|
Apr 2, 2026
10w ago
|
8-K
| $1.51 $1.50 | ▼ −0.66% | ▼ −1.14% | $0.9900 (−34.44%) |
|
Mar 31, 2026
10w ago
|
8-K
| $1.01 $1.02 | ▲ +0.99% | ▲ +0.24% | $0.9900 (−1.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access